# Janssen Vaccines & Prevention B.V. trials: 49 (2026)

ClinicalTrials.gov lists 49 trials with Janssen Vaccines & Prevention B.V. as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Janssen Vaccines & Prevention B.V.: 49 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-vaccines-and-prevention-b-v

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 13, 2023 | NCT05901636 | A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults | Janssen Vaccines & Prevention B.V. | Phase 1/2 | Completed | Influenza Prevention | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05901636) |
| April 14, 2022 | NCT05327816 | A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older | Janssen Vaccines & Prevention B.V. | Phase 1/2 | Terminated | Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05327816) |
| November 1, 2021 | NCT05101486 | A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Respiratory Syncytial Virus Prevention | 755 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05101486) |
| October 25, 2021 | NCT05091307 | A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | COVID-19 Prevention | 861 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05091307) |
| October 19, 2021 | NCT05083585 | A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Respiratory Syncytial Virus Prevention | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05083585) |
| October 8, 2021 | NCT05071313 | A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65... | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention | 777 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05071313) |
| October 7, 2021 | NCT05070546 | A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Respiratory Syncytial Virus Infection Prevention | 1,124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05070546) |
| August 16, 2021 | NCT05007080 | A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive | Janssen Vaccines & Prevention B.V. | Phase 2 | Completed | Coronavirus Disease-2019 (COVID-19) Prevention | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05007080) |
| August 10, 2021 | NCT04999111 | A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or... | Janssen Vaccines & Prevention B.V. | Phase 2 | Completed | Coronavirus Disease | 1,541 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04999111) |
| June 1, 2021 | NCT04908722 | A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | COVID-19 Prevention | 1,609 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04908722) |
| June 1, 2021 | NCT04908683 | A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV)... | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Respiratory Syncytial Viruses, Lower Respiratory Tract Disease | 25,236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04908683) |
| May 20, 2021 | NCT04894305 | A Study of Ad26.COV2.S in Healthy Adults (COVID-19) | Janssen Vaccines & Prevention B.V. | Phase 1 | Completed | Healthy | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04894305) |
| February 21, 2021 | NCT04765384 | A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) | Janssen Vaccines & Prevention B.V. | Phase 2 | Completed | COVID-19 Prevention | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04765384) |
| November 4, 2020 | NCT04614948 | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 | 31,835 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04614948) |
| September 21, 2020 | NCT04556526 | A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Healthy | 4,031 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04556526) |
| September 2, 2020 | NCT04535453 | A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents | Janssen Vaccines & Prevention B.V. | Phase 2 | Completed | Healthy | 635 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04535453) |
| August 10, 2020 | NCT04505722 | A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages... | 44,325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04505722) |
| July 1, 2020 | NCT04453202 | A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults | Janssen Vaccines & Prevention B.V. | Phase 2 | Completed | Healthy | 459 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04453202) |
| June 18, 2020 | NCT04436276 | A Study of Ad26.COV2.S in Adults (COVID-19) | Janssen Vaccines & Prevention B.V. | Phase 1/2 | Completed | Covid-19 Prevention | 1,085 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04436276) |
| January 14, 2020 | NCT04228783 | A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Ebola | 974 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04228783) |
| June 11, 2019 | NCT03982199 | A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed... | Janssen Vaccines & Prevention B.V. | Phase 2 | Terminated | Respiratory Syncytial Viruses, Respiratory Tract Diseases | 5,815 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03982199) |
| May 28, 2019 | NCT03964415 | A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C... | Janssen Vaccines & Prevention B.V. | Phase 3 | Completed | Healthy | 3,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03964415) |
| April 29, 2019 | NCT03929757 | A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants | Janssen Vaccines & Prevention B.V. | Phase 2 | Completed | Ebola Virus Disease | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03929757) |
| January 7, 2019 | NCT03795441 | A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults | Janssen Vaccines & Prevention B.V. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03795441) |
| August 1, 2018 | NCT03610581 | Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components... | Janssen Vaccines & Prevention B.V. | Phase 1/2 | Terminated | Human Papillomavirus Infections | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03610581) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 11 |
| Phase 2 | 14 |
| Phase 3 | 15 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 44 |
| Terminated | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemorrhagic Fever, Ebola | 7 |
| Acquired Immunodeficiency Syndrome | 4 |
| Hemorrhagic Fevers, Viral | 4 |
| COVID-19 | 2 |
| Respiratory Tract Diseases | 1 |
| Influenza, Human | 1 |
| Respiratory Tract Infections | 1 |
| Papillomavirus Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Walk-in clinics in the United States](https://specstream.ai/data/businesses/walk-in-clinics/united-states)
- [Customs brokers in the United States](https://specstream.ai/data/businesses/customs-brokers/united-states)
- [Litigation law firms in the United States](https://specstream.ai/data/businesses/litigation-law-firms/united-states)
- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Cabinet makers in the United States](https://specstream.ai/data/businesses/cabinet-makers/united-states)
- [Hotel bars in the United States](https://specstream.ai/data/businesses/hotel-bars/united-states)
